These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3245408)

  • 1. [Studies on the mechanisms of the antiatherogenic effect of Ca-antagonists].
    Birou S
    Igaku Kenkyu; 1988 Apr; 58(2):77-84. PubMed ID: 3245408
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel blockers and atherosclerosis.
    Sowers JR
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):3-9. PubMed ID: 2220798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of diltiazem on plaque cells of primary and restenosed lesions].
    Voisard R; Dartsch PC; Bauriedel G; Höfling B; Betz E
    Vasa Suppl; 1989; 27():241-3. PubMed ID: 2623504
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium channel antagonists. What do the second-generation agents have to offer?
    Salerno SM; Zugibe FT
    Postgrad Med; 1994 Jan; 95(1):181-90. PubMed ID: 8278298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of anti-atheromatous properties of calcium channel inhibitors].
    Drici MD; Coccoz F; Morand P; Lapalus P
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():161-5. PubMed ID: 1285697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of diltiazem on single smooth muscle cells and on neuromuscular transmission in the vascular bed.
    Kuriyama H; Ito Y; Suzuki H; Kitamura K; Itoh T; Kajiwara M; Fujiwara S
    Circ Res; 1983 Feb; 52(2 Pt 2):I92-6. PubMed ID: 6299608
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium antagonists and atherosclerosis.
    Betz E; Weiss HD; Heinle H; Fotev Z
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S71-5. PubMed ID: 1725009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Ca antagonists on Ca fluxes in resistance vessels.
    Cauvin C; Saida K; van Breemen C
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S287-90. PubMed ID: 6184554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
    Opie LH
    Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiatherosclerotic effects of calcium antagonists.
    Paoletti R; Bernini F; Corsini A; Soma MR
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S6-10. PubMed ID: 8852538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium antagonists decrease migration and proliferation activity of human plaque monocytes].
    Heimerl J; Höfling B; Heidemann P; Emberger C; Kandolf R; Bauriedel G
    Vasa Suppl; 1992; 35():134-6. PubMed ID: 1481018
    [No Abstract]   [Full Text] [Related]  

  • 13. Endothelium, atherosclerosis and calcium channel blockers.
    Biswas TK
    J Indian Med Assoc; 2003 Jul; 101(7):428-31. PubMed ID: 14748381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor effects of diltiazem, nicardipine, nifedipine and verapamil on the norepinephrine-induced contractions of the canine saphenous vein in calcium-free medium.
    Saïag B; Milon D; Bentue-Ferrer D; Allain H; Rault B; Van den Driessche J
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):255-69. PubMed ID: 8008975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
    Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The participation of the prostacyclin-thromboxane system in the mechanism of the action of calcium antagonists].
    Kazanova GV; Chichkanov GG
    Eksp Klin Farmakol; 1993; 56(4):22-4. PubMed ID: 8220008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension: calcium-blocking agents in treatment.
    Ambrose JE
    J Am Osteopath Assoc; 1984 Jan; 83(5):353-60. PubMed ID: 6321407
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium antagonists and atherosclerosis.
    Schachter M
    Int J Cardiol; 1997 Dec; 62 Suppl 2():S9-15. PubMed ID: 9488190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antihypertensive therapy and vascular wall protection with special reference to calcium antagonists].
    Faulhaber HD
    Z Arztl Fortbild (Jena); 1993; 87(9 Suppl 5):1-5. PubMed ID: 8237075
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the pathogenesis of atherosclerosis.
    She M; Yu L
    Chin Med J (Engl); 1997 Jan; 110(1):14-21. PubMed ID: 9594315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.